Search

Displaying results 1321 - 1330 of 1804 in total
  1. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter catabolism via

  2. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    It may also alter enamel surface morphology via enamel mineral loss and surface roughening [A32336].

  3. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...

  4. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into...

  5. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    These results are consistent with the transport of glisoxepide via the transport system for the unconjugated bile acid cholate. [A31819,A31820]

  6. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but

  7. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen].

  8. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.

    Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors, Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors
  9. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formati...

  10. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Newer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200].

    Categories: Dopamine D2 Receptor Agonists